همایش ملی بیوانفورماتیک ایران

صفحه اصلی / 4th international edition and 13th Iranian Conference on Bioinformatics

Identification of Therapeutic Biomarkers in Patients with Rheumatoid Arthritis Treated with Methotrexate

نویسندگان :

Narges Yaghoobi¹ Tannaz Araei² Sara Abedi³ Mohsen Goharinia⁴ Mohammad Mehdi Naghizadeh⁵

1- دانشگاه علوم پزشکی فسا 2- دانشگاه علوم پزشکی فسا 3- دانشگاه علوم پزشکی فسا 4- دانشگاه علوم پزشکی فسا 5- دانشگاه علوم پزشکی فسا

کلمات کلیدی :

miRNA،Rheumatoid Arthritis،Methotrexate،Regulatory network

چکیده :

Abstract: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and joint destruction, significantly impacting patients' quality of life [1]. Methotrexate (MTX) remains the cornerstone of RA treatment; however, variability in therapeutic response presents a challenge, prompting researchers to explore molecular predictive biomarkers to optimize patient outcomes [2]. non-coding RNAs, such as miRNAs have recently gained attention due to their regulatory roles in gene expression [3]. Emerging evidence suggests that non-coding RNAs play crucial roles in autoimmune diseases, including RA. Gene expression profiles (GSE45867) were downloaded from the Gene Expression Omnibus. Differentially expressed genes and miRNAs were identified using the GEO2R analysis. Enrichr was used to obtain the pathway and biological process. miRTarbase database were used to receive miRNAs. The miRNA-mRNA interaction was reconstructed with Cytoscape software. Functional enrichment analysis identified several pathways and biological processes associated with PIP, including Interferon Signaling, Immunoregulatory Interactions between Lymphoid and Non-Lymphoid Cells, Signaling by Interleukins, Transforming Growth Factor Beta (TGF-β) Family Signaling, and Neutrophil Degranulation. The results of this study showed that miR-124-3p, miR-101-3p, miR-16-5p and miR-26b-5p have most important regulatory roles. This study identifies that these miRNAs may serve as therapeutic biomarkers in predicting the response to methotrexate treatment.